Myocardial Infarction in patients with severe beta thalassaemia: A case series
Author:
Premawardhena Anuja1, De Silva Shamila1, Rajapaksha Megha2, Ratnamalala Visaka3, Nallarajah Jemimah3, Galappatthy Gamini3
Affiliation:
1. University of Kelaniya 2. Adolescent and Adult Thalassaemia Centre 3. National Hospital of Sri Lanka
Abstract
Abstract
Back Ground: Cardiac disease remains a dominant if not the most important cause of morbidity and mortality in patients with thalassaemia, particular in those with thalassaemia major. Myocardial infarction and coronary artery disease however is rarely reported.
Case Presentations: Three older patients with three distinct thalassaemia syndromes presented with acute coronary syndrome. Two were heavily transfused whilst the other was a minimally transfused patient. Both heavily transfused patients had ST-elevation myocardial infarctions (STEMI) while the minimally transfused patient had unstable angina. Coronary angiogram (CA) was normal in two patients. One patient who developed a STEMI had a 50% plaque. All three were managed as standard ACS, although the aetiology appeared non-atherogenic.
Conclusions: The exact etiology of the presentation, remains a mystery and therefore the rational use of thrombolytic, carrying out angiogram in the primary setting, using and continuing antiplatelet and high dose statins all remains unclear in this sub group of patients.
Publisher
Research Square Platform LLC
Reference14 articles.
1. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance;Modell B;J Cardiovasc Magn Reson,2008 2. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Arnett, Donna K, Blumenthal, Roger S, Albert, Michelle A, et al. Circulation 2019. 140 (11) e596–646. 3. Musallam KM, Vitrano A, Meloni A, Pollina SA, Karimi M, El-Beshlawy A, Hajipour M, Di Marco V, Ansari SH, Filosa A, Ricchi P, Ceci A, Daar S, Vlachaki E, Singer ST, Naserullah ZA, Pepe A, Scondotto S, Dardanoni G, Bonifazi F, Sankaran VG, Vichinsky E, Taher AT, Maggio A. Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia. Haematologica. 2021 Sep 1;106(9):2489–2492. doi: 10.3324/haematol.2021.278684. PMID: 33882642; PMCID: PMC8409024. 4. The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?;Vitrano A;Br J Haematol,2017 5. Premawardhena AP, Ediriweera DS, Sabouhanian A, Allen A, Rees D, de Silva S, Perera W, Katugaha N, Arambepola M, Yamashita RC, Mettananda S, Jiffry N, Mehta V, Cader R, Bandara D, St Pierre T, Muraca G, Fisher C, Kirubarajan A, Khan S, Allen 6. Lamabadusuriya S, Weatherall SP, Olivieri DJ. NF. Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study. Lancet Glob Health. 2022 Jan;10(1):e134-e141. doi: 10.1016/S2214-109X(21)00446-0. Epub 2021 Nov 26. PMID: 34843671; PMCID: PMC8672061.
|
|